Tuesday, October 4, 2022


Biotechnology News Magazine

LabMinds Successfully Receives Approval for Use in a GMP Certified Laboratory

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

LabMinds®, Inc., a pioneer in automation for solution preparation in life sciences, today announced that the Revo has been approved for use in a Good Manufacturing Practice (GMP) certified laboratory in a Top 10 Pharmaceutical company.

LabMinds is an internationally recognized, award-winning robotics company in the pharmaceutical industry. This approval follows a 12-month product development collaboration with a European based pharmaceutical leader. GMP certification was achieved through a series of rigorous process reviews and upgrades. This GMP designation demonstrates that the Revo fulfills the high degree of quality, traceability, documentation and consistency required by the pharmaceutical industry.

“On behalf of the LabMinds team, I would like to thank everyone involved in this GMP product development project. This represents a significant milestone in our commercial growth plans to bring new products and services to market,” says Jeff Caputo, President and CEO of LabMinds. “Our customers clearly want to leverage the benefits of our Revo technology in their regulated laboratories. We look forward to launching our GMP product offering globally this year.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine